31 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22755 | Absence of metastasis | Spyridon Sideris | Ureters - bladder - urethra | Roche | WO29636 | Trial closed | WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti?Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 22834 | Intermediate or poor risk metastatic clear cell renal cell carcinoma in 1st line treatment. | Nieves Martinez Chanza | Multiple | Exelixis | XL184-313 | Trial closed for recruitment | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
| 22739 | *Single indeterminate renal mass <=7cm *scheduled nephrectomy within 90 days from planned Zr-TLX250 administration |
Carlos Artigas Guix | Kidney | Telix International Pty Ltd | ZIRCON | Trial closed | A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON Study) | carlos.artigas@hubruxelles.be | 3 | 3 |